Navigation Links
VascoScrew CC 6/60 M

ProductsVascoScrew CC 6/60 M
Company Vascomed
Item VascoScrew CC 6/60 M
Features The VascoScrew 6/60 S can be placed quickly and safely in the ventricle, appendage or the lateral wall of the atrium with low thresholds and high sensing amplitudes. High flexibility and security is provided quadrifilar coil and the choice of high-grade materials.
Description VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
Info Vascomed
Customer Service: +49-180 5-82726633
Web site: http://www.vascomed.de/

Related medicine products :

1. VascoScrew E 5/60 PU S
2. VascoScrew E 5/60 PU M
3. VascoScrew CC 5/60 PU M
4. VascoScrew CC 5/60 PU S
5. VascoScrew E 6/60 S
6. VascoScrew E 6/60 M
7. VascoScrew P 6/60 M
8. VascoScrew E 8/60 S
9. VascoScrew CC 6/60 S
10. VascoScrew E 8/60 M
11. VascoScrew CC 8/60 M
The CIC Pro Clinical Information Center brings together vital patient information from multiple monitoring devices....
... Alaris System integrates drug infusion,with patient ... a single, modular platform. With multiple ... modules as you,need them, keeping the ... a minimum while managing the unique ...
... Gemini Family of infusion pumps ... a collective series of administration ... line offers a wide variety ... sets, each featuring the patented ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
Medicine Products:
(Date:11/27/2014)... At The Little Gym, we know that being ... surprise when a recent study confirmed that regular physical ... Journal of Pediatrics found that “Promoting physical activity ... school years may be important not only for health, ... two groups of children; those that were engaging in ...
(Date:11/27/2014)... 27, 2014 Ethane Web Technologies, which ... announced online reputation management service. , The company ... about the world of internet marketing and algorithms of ... , Ethane Web Technologies does not work with the ... the project to reach a conclusion what will work ...
(Date:11/27/2014)... November 27, 2014 VeloReality Inc. ... new Real Life Videos (RLVs) of world-famous velo courses for ... as well as other popular indoor velo trainers. Two dozen ... worldwide before the end of November -- in time ... total number of rides in the VeloReality collection to over ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Serious Buyer, ... for vintage 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum concert posters. ... bands played at the University of Alabama. Jimi Hendrix ... to Hawley, “It started with Gary Weinberger who was ... at University Programs Council. The council was responsible for ...
(Date:11/26/2014)... Angeles, CA (PRWEB) November 26, 2014 ... to treat themselves this holiday season! With Parsa Mohebi ... incredible 10% off of their next FUE procedure, making ... transplant. , FUE—which stands for “Follicular Unit Extraction”—is an ... advantages over traditional “strip” Follicular Unit Transplantation (FUT). FUE, ...
Breaking Medicine News(10 mins):Health News:Ethane Web Technologies Announces Online Reputation Management Service 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3Health News:Serious Buyer Announces His Search For Vintage 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum Concert Posters 2Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2
... Mich. Scientists at the University of Michigan Comprehensive Cancer ... cancer stem cells, the small number of cells in a ... that breast cancer stem cells are regulated by a type ... These cells are drawn from the bone marrow to the ...
... Controlling blood pressure is not only a medical challenge, ... required to strictly adhere to a treatment plan that ... the ideas of wellness and health are also powerful ... This is especially true in the African American ...
... recent study by Merikangas and colleagues published in the ... American Academy of Child and Adolescent Psychiatry (JAACAP) ... with severely impairing mental disorders ever receive treatment for ... one third of adolescents with any mental disorder received ...
... Heart disease is the leading cause of death for ... disease is more than just one disease; there are many ... blood pressure, diabetes or other causes. In lipotoxic cardiomyopathy, for ... cells. Obesity and high-fat diets are major risk factors for ...
... According to the World Health Organisation (WHO), an estimated 322,000 ... fire and in many of these cases death could have ... intervention, when major burn patients have insufficient skin left to ... skin has literally to be grown from the patient,s own ...
... Reporter , MONDAY, Jan. 17 (HealthDay News) -- Few ... measure up, according to new research. Dermatologists evaluated ... from the sun,s ultraviolet rays and found only a ... can penetrate glass. "The vast majority of the ...
Cached Medicine News:Health News:U-M researchers find indirect path to attack breast cancer stem cells 2Health News:Storytelling may help control blood pressure in African-Americans 2Health News:Adolescents with severe mental disorders have never received treatment 2Health News:A different path to fat-related heart disease 2Health News:Nanotech medicine 2Health News:Nanotech medicine 3Health News:Nanotech medicine 4Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 2Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 3
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2